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Précis - The art and science of oro-maxillo-facial reconstruction is of great 
interest for contemporary oral and maxillofacial surgeons; in search for better 
bioengineering strategies and biomaterials: a core driver for bio-dental research, 
today. Leukocyte and Platelet-Rich Fibrin (L-PRF) is a 3-D autogenous 
biomaterial obtained via the simple and rapid centrifugation of whole blood 
patient samples, in the absence of anti-coagulants, bovine thrombin, additives 
or any gelifying agents. A relatively new “revolutionary” step in 2nd generation 
platelet concentrate-based therapeutics, the clinical safety, and more so, efficacy 
and effectiveness of L-PRF remains highly debatable, whether due to significant 
variabilities in preparation protocols, limited evidence-based scientific and clinical 
literature and/or inadequate understanding of its bio-components. 
Despite significant improvements, our current clinical armamentarium, 
strategies, procedures and approaches used to reconstruct and heal complex 
oro-dental and maxillo-facial defects, including different bone grafting 
methods are deemed restricted, daily. Often multi-factorial; whether due 
to limited self-renewal capacity of the defect and/or limited donor supply, 
increased morbidity, risk of antigenicity and foreign body reactions, associated 
with the grafts used. Operative associated time and cost contribute as well. 
Regenerative tissue engineering directs the ongoing development of novel 
biomaterials for use in oro-dental surgery; alveolar bone regeneration and 
repair, is a fine example. Localized site development, sinus lift and socket 
preservation, are others.2 The family and sub-families of ‘Platelet Concentrates’ 
are certainly incessantly promising.
Briefly, Platelet Concentrates (PCs) are autologous blood extracts obtained 
through centrifugation of whole blood samples. The preparation procedure 
allows the gathering and concentration of platelets and other therapeutic 
blood constituents (fibrinogen/fibrin, growth factors, leukocytes and 
circulating cells), in clinically usable preparations (surgical adjuvants), which 
may promote hard and soft tissue wound healing and regeneration.3
Despite promising clinical observations, overall effectiveness remains 
debatable mostly due to mixed and variable clinical outcomes, limited high-
quality evidence-based literature, and poor characterization of end-products 
and preparation protocols; and - until recently - lack of proper terminology 
systems to classify such preparations. Indeed, to the best of our knowledge, 
the first consensus appeared in 2009, describing four PC sub-families, 
based on extant or hypothesized variability in biological content (fibrin/
cell), properties (gelification, for example) and potential applications: Pure 
Platelet-Rich Plasma (P-PRP), Leukocyte and Platelet-Rich Plasma (L-PRP), 
Pure Platelet-Rich Fibrin (P-PRF) and Leukocyte and Platelet-Rich Fibrin 
(L-PRF).4 Today, the L-PRF sub-family2-4 is receiving utmost attention, due 
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to simplicity, malleability and probable cost-effectiveness; a 
revolutionary dynamic novelty in contemporary oro-maxillo-
facial tissue repair and regeneration.
L-PRF is an autologous platelet concentrate of whole venous 
blood.4,5 A slowly- and strongly-polymerized fibrin gel rich in 
growth factors, platelets, leukocytes (almost half of the initial 
blood harvest) and lymphocytes, is collected following simple 
and rapid (~10 minutes) centrifugation of blood in vacutainer 
tubes, without anti-coagulant, bovine thrombin, additives or 
any other gelifying agent (i.e. under naturally physiological 
concentrations of autologous thrombin). Preparation protocols 
vary, recommendations for reproducibility are provided in 
Figure 1. The gathered clot (or biomaterial) is stable, resilient, 
strong, adhesive and malleable, and it can be cut or adapted 
into different anatomical defects and applications: used 
directly as filling material, mixed with bone grating material, 
or compressed into a strong fibrin membrane. Alongside this 
established clinical ease of use and handling, the biochemical 
composition of the L-PRF by-products provides it, up to an 
extent, with attractive hemostatic, angiogenic, osteogenic, 
anti-inflammatory, anti-microbial, pain-inhibitory and 
wound healing characteristics;4-8 an open-ended topic of 
ongoing debate in the scientific and clinical community 
worldwide.6-9 Indeed, despite promises, the accumulating 
in vitro and in vivo results regarding soft- and hard-tissue 
regeneration, have been fueling controversies especially 
regarding the “real extent” of clinical effects/effectiveness 
and continues to be the matter of vigorous debate due to key 
biological and technological issues.
There is a need to address such questions and concerns, with 
prospective long-term post-operative evaluation of L-PRF use, 
from high-quality Randomized and Controlled Clinical Trials, 
and not solely from in vitro, in vivo and case report studies.
Most prominent L-PRF applications in the literature 
include the treatment of periodontal intra-bony defects (with 
or without open flap, versus de-mineralized freeze-dried bone 
allografts or Bio-Oss® constructs, for example); treatment of 
furcation defects (versus. open flap debridement, for grade II 
mandibular defects); treatment of Miller Class I/II gingival 
recessions (versus coronally-advanced flaps, connective tissue 
grafts or sub-epithelial connective tissue grafts); and sinus floor 
augmentation procedures (lateral osteotomy window versus 
using an absorbable covering membrane, such as Geistlich 
Bio-Gide®). With a snowballing sum of studies (case reports/
series, mostly), it is challenging for clinicians and researchers 
to obtain the “bottom line” on the “real” benefits of L-PRF. 
Crucial data about L-PRF preparation and characterization 
are often forgotten or omitted. Increasing indication of 
intrinsic centrifuge characteristics (i.e. vibration) pointedly 
impact the biomaterial’s composition/architecture, cytokine 
release kinetics and cell integrity/viability;8,9 key variables 
requiring proper documentation in future publications.
With several “new” and “revolutionary” centrifuges and 
kits being continuously developed and commercialized 
under confusing or mystifying “PRF-related” labels, basic 
characterization of tested “PRF” preparations (i.e. histology 
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Figure 1.   Contemporary Recommendations for L-PRF Clinical Preparation Protocol
For the most reproducible and clinically-usable L-PRF clots and membranes, 
and for the best possible clinical outcome, the following protocol is recommended:
Collect a 5-9mL whole venous blood sample into 2-3 sterile 6mL 
glass-coated plastic vacutainer tubes (without anti-coagulant).
Centrifuge immediately for 10-12 minutes at 2700/3000 
revolutions per minutes (rpm) using a high-quality table 
centrifuge. 
Collect L-PRF clot carefully from the middle portion of the tubes. 
Typically, three phases should be evident in the tube. UPPER: 
straw-colored acellular plasma (PPP), MIDDLE: yellowish fibrin 
clot (FC); and LOWER: red-colored lower fraction containing red 
blood cells (RBCs). Remove the upper layer in order to collect the 
middle fraction: 2mm below the lower dividing line.
The collected clot can then be used directly as filling material, 
mixed with bone grating material (L-PRF plug/block) or 
compressed into a stong L-PRF membrane, using a surgical box 
designed to prepare it without damage.
REMINDER: Quick handling is critical in order to obtain bioactive L-PRF clots charged with serum and platelets.
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and SEM analysis) should be encouraged as “minimum 
criteria” to assess the final product and preparation quality. 
In this context, Choukroun’s “original” L-PRF (5-10mL 
whole blood centrifuged at 2700-3000rpm or 400g for 10-
12 minutes) should be considered the “current gold-standard” 
preparation, a validated protocol.10 Recent publication of 
the first detailed clinical “Step-by-Step” guide-line useful 
for L-PRF (Avalaible at: https://kuleuvencongres.be/
ENHD2018) supports the aforementioned protocol and 
indeed encourages its  implementation in future clinical 
trials. Because of hype, readers should be aware of probable 
publication bias within the L-PRF literature, as studies 
reporting “significant” benefits or effects are far more likely 
to be published than those with modest or no results. Quality 
of reporting of RCTs does not necessarily describe the value 
of L-PRF use, especially since most of reviewed literature 
report some benefit in early wound healing, bone formation/
maturation and post-surgical pain inhibition or control. 6,9
Now, L-PRF may still be designated as an innovative tool 
for contemporary oro-maxillo-facial tissue reconstruction 
and bioengineering. While existing reports suggest that 
L-PRF improves early wound healing and promotes post-
surgical bone formation/maturation, it is noteworthy that 
a clearer consensus seems present regarding its significant 
beneficial impact on post-surgical pain and discomfort 
control, regardless of the type of procedure.6,9,10 
In a pilot prospective observational study9 involving 
a cohort of 11 patients receiving a Wilcko’s modified 
periodontally accelerated osteogenic orthodontics – a surgical 
procedure which allows faster tooth movement by combining 
orthodontic forces with corticotomy and grafting of alveolar bone 
plates – technique with L-PRF, accelerated wound healing 
with no signs of infection or adverse reactions. Post-surgical 
pain, inflammation and infection were recorded for 10 days 
post-operatively, while the overall orthodontic treatment 
and post-treatment stability were followed up to 2 years. 
Interestingly, our data analysis revealed complete resolution 
achieved in all patients by day 8, average orthodontic 
treatment time calculated at 9.3 months and all cases were 
stable throughout. Thus, it was concluded that combining 
L-PRF (within the graft and as a covering membrane) with 
traditional bone grafts (L-PRF plug/block) accelerates wound 
healing and reduces post-surgical pain, inflammation, edema, 
and infection without interfering with tooth movement 
or post-orthodontic stability, over an extended two-year 
period, thereby alleviating the need for analgesics and anti-
inflammatory medications.
It is useful to re-emphasize that new L-PRF preparations, 
unlike its predecessors, tend to function more as biologically-
active biomaterials/scaffolds for autologous cells and growth 
factors delivery; a “living tissue” preparation for natural 
guided tissue regeneration and not simply a “growth factor-
rich” surgical adjuvant.  This remains an un-explored territory 
in dental bioengineering research, and better RCTs are 
needed to confirm the reported “clinical observations”, whilst 
other scientific studies are awaited to properly characterize 
or elucidate the underlying mechanism(s) of action, from 
the physical, chemico-biological and mechanico-rheological 
aspects of L-PRF, for a more practical understanding for its 
use and application.
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